公开(公告)号：US12246020B2

公开(公告)日：2025-03-11

申请号：US18517156

申请日：2023-11-22

Applicant: InventisBio Co., Ltd.

Inventor： Xing Dai ,  Yueheng Jiang ,  Yanqin Liu

IPC: C07D487/04 ,  A61K31/505 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  C07D471/04

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

公开(公告)号：US11865115B2

公开(公告)日：2024-01-09

申请号：US17591816

申请日：2022-02-03

Applicant: InventisBio Co., Ltd.

Inventor： Xing Dai ,  Yueheng Jiang ,  Yanqin Liu

IPC: C07D487/04 ,  A61K31/505 ,  A61P35/00 ,  A61K31/519 ,  A61K45/06 ,  C07D471/04

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D471/04 ,  C07B2200/13

Abstract: Provided herein are compounds, crystalline forms, and pharmaceutical compositions of Compound 1 and/or Compound 2. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

公开(公告)号：US11685720B2

公开(公告)日：2023-06-27

申请号：US17748134

申请日：2022-05-19

Applicant: INVENTISBIO CO., LTD.

Inventor： Xing Dai ,  Yueheng Jiang

IPC: C07D213/70 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/522

CPC classification number: C07D213/70 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/522 ,  C07B2200/13

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to thiobutyrate compounds, such as Compound (1) and its salts (such as sodium, potassium, and calcium salt), as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as gout and hyperuricemia.

公开(公告)号：US20220371996A1

公开(公告)日：2022-11-24

申请号：US17748134

申请日：2022-05-19

Applicant: INVENTISBIO CO., LTD.

Inventor： Xing DAI ,  Yueheng JIANG

IPC: C07D213/70 ,  A61K31/426 ,  A61K31/522 ,  A61K31/4418

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to thiobutyrate compounds, such as Compound (1) and its salts (such as sodium, potassium, and calcium salt), as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as gout and hyperuricemia.

公开(公告)号：US11498921B1

公开(公告)日：2022-11-15

申请号：US17499230

申请日：2021-10-12

Applicant: INVENTISBIO CO., LTD.

Inventor： Yueheng Jiang

IPC: C07D403/04 ,  A61P35/02 ,  A61P35/04 ,  A61K31/506 ,  C07D471/04 ,  C07D401/04 ,  C07D403/14 ,  C07D405/14 ,  C07D401/14 ,  C07D413/04 ,  C07D417/04 ,  A61K31/437

Abstract: The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

公开(公告)号：US20240343727A1

公开(公告)日：2024-10-17

申请号：US18578677

申请日：2022-08-16

Applicant: InventisBio Co., Ltd. ,  InventisBio LLC

Inventor： Xianhai HUANG ,  Younong YU ,  Haotao NIU ,  Hong YANG ,  Shanshan WANG ,  Jifang WENG ,  Yaolin WANG ,  Xing DAI

IPC: C07D471/04 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/052 ,  C07D491/107

CPC classification number: C07D471/04 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/052 ,  C07D491/107

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in treating cancer.

公开(公告)号：US20240208967A1

公开(公告)日：2024-06-27

申请号：US18515890

申请日：2023-11-21

Applicant: INVENTISBIO CO., LTD.

Inventor： Yueheng JIANG

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  A61P35/02 ,  A61P35/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  A61P35/02 ,  A61P35/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

公开(公告)号：US20230357233A1

公开(公告)日：2023-11-09

申请号：US18042872

申请日：2021-08-26

Applicant: INVENTISBIO CO., LTD. ,  INVENTISBIO LLC

Inventor： Xing DAI ,  Hong YANG ,  Xianhai HUANG ,  Haotao NIU ,  Zixing HAN ,  Zhenwu WANG ,  Qiang ZHANG ,  Yanqin LIU ,  Yueheng JIANG ,  Liangshan TAO ,  Jifang WENG ,  Zhe SHI ,  Yaolin WANG

IPC: C07D471/04 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K45/06 ,  C07D519/00

Abstract: Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRASG12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.

公开(公告)号：US20230263782A1

公开(公告)日：2023-08-24

申请号：US18010735

申请日：2021-06-18

Applicant: INVENTISBIO CO., LTD.

Inventor： Xing DAI ,  Xiaomei WANG ,  Yanqin LIU ,  Yueheng JIANG ,  Yaolin WANG

IPC: A61K31/437 ,  A61K9/16 ,  A61K45/06 ,  A61K9/20 ,  A61K47/18

CPC classification number: A61K31/437 ,  A61K9/1694 ,  A61K45/06 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K47/18

Abstract: Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to Selective Estrogen Receptor Degraders, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as breast cancer.

公开(公告)号：US20220213066A1

公开(公告)日：2022-07-07

申请号：US17611458

申请日：2020-05-15

Applicant: INVENTISBIO CO., LTD. ,  BETTA PHARMACEUTICALS CO., LTD

Inventor： Xing DAI ,  Yueheng JIANG ,  Yanqin LIU

IPC: C07D403/04

Abstract: The present invention relates to a salt of a Compound 1 and polymorphs thereof, and pharmaceutical compositions containing the same, wherein the salt is preferably hydrochloride, phosphate, tosilate, benzene sulfonate, succinate, sulfate, monohydrobromate, dihydrobromate, etc. The present invention further relates to methods for preparing the described substances, their uses, and pharmaceutical preparations containing these salts and crystalline forms.